% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Hemminki:291288,
      author       = {K. Hemminki$^*$ and F. Zitricky and A. Försti$^*$ and A.
                      Hemminki},
      title        = {{S}urvival in {E}lderly {O}varian {C}ancer {R}emains
                      {C}hallenging in the {N}ordic {C}ountries.},
      journal      = {Cancers},
      volume       = {16},
      number       = {12},
      issn         = {2072-6694},
      address      = {Basel},
      publisher    = {MDPI},
      reportid     = {DKFZ-2024-01371},
      pages        = {2198},
      year         = {2024},
      note         = {#EA:Z999#},
      abstract     = {Despite treatment having improved through intensive
                      surgical procedures and chemotherapy-and more recently,
                      targeted therapies-ovarian cancer is the most fatal female
                      cancer. As such, we wanted to analyze age-specific survival
                      trends for ovarian cancer in Denmark, Finland, Norway and
                      Sweden over the past 50 years, with a special aim of
                      comparing survival development between the age groups.We
                      modelled survival data from the NORDCAN database for 1-, 5-
                      and conditional 5/1-year relative (between years 1 and 5)
                      survival for ovarian cancer from 1972 to 2021.Young patients
                      had a $70\%$ 5-year survival while the survival was only
                      $30\%$ for the oldest patients. Conditional survival showed
                      that survival between years 1 and 5 did not improve for
                      patients older than 60 years throughout the 50-year period,
                      during which time the gaps between the youngest and the
                      oldest patients widened.Improvement in 1-year survival was
                      so large that it masked the modest development between years
                      1 and 5, resulting in a widening age disparity in 5-year
                      survival. The current treatment practices, which appear
                      increasingly effective for younger patients, have not helped
                      remedy the large age differences in ovarian cancer survival.
                      Early detection methods and therapeutic innovations are
                      urgently needed, and aged patients need a special focus.},
      keywords     = {carboplatin cancer control (Other) / prognosis (Other) /
                      relative survival (Other) / treatment (Other)},
      cin          = {Z999 / B062 / HD01},
      ddc          = {610},
      cid          = {I:(DE-He78)Z999-20160331 / I:(DE-He78)B062-20160331 /
                      I:(DE-He78)HD01-20160331},
      pnm          = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
      pid          = {G:(DE-HGF)POF4-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:38927904},
      doi          = {10.3390/cancers16122198},
      url          = {https://inrepo02.dkfz.de/record/291288},
}